RE: Is Volatility Risk?26 Apr 2024 10:41
Your point about 'old device usually used to mean the company is for sale' seems spot on. In the RNS they even say 'Currently, the review is not actively considering an offer for the company'. From their timeline in the presentation they seem in no hurry to start the trial which, now that you said that, seems to be a strong call for selling the company (get your offers in!) before the trial. Which is really no bad news as it seems clear this would be handled better by a larger pharma co. The offer would likely be well in excess of current valuations given the current market cap and potential for the drug. So looks like this will be sold within the year (before cash runs out?). But I am generally wrong but even a stopped clock is right once a day (I mean twice).